Replies to post #441580 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

As others have pointed out, the FDA is not slow-rolling review of Anavex 2-73 for AD because Anavex has not even submitted an application to the FDA for review for this indication.

Historically, indications with zero effective therapies often see additional extremely marginal-to-ineffective therapies approved (glatiramer acetate and beta interferons for MS, for example, or therapies for muscular distrophy, or recently a therapy for ALS.) It is not surprising that a couple of very, very marginal therapies were approved for AD.

When Anavex submits its NDA it will be in good shape to be approved.

[rayovac812]

It's almost as if having millions in lobbying money greases the wheels.

What is interesting is that Dr. Jin didn't go to any of the wheel greasers, rather he came on board to assist AVXL.